Devonian’s Phase II/III Thykamine paediatric study secures Health Canada approval

Devonian Health Group has received authorisation from Health Canada for its CTA to begin a Phase II/III study of Thykamine cream to treat mild-to-moderate atopic dermatitis in paediatric patients.

The post Devonian’s Phase II/III Thykamine paediatric study secures Health Canada approval appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.